- Date2024-09-10
Publication of Review Result of the Tenth Pharmaceutical Reimbursement Evaluation Committee of 2023
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 10th Pharmaceutical Reimbursement Evaluation Committee in 2023 as follows.
|
product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Zavicefta Inj. 2g/0.5g (Ceftazidime /Avibactam) |
Pfizer Korea Inc. |
1. Complicated intra-abdominal infection (cIAI) 2. Complicated urinary tract infection (cUTI) 3. Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) |
Reimbursement is adequate when accepted at or below assessed value. |
|
Bosulif Tab. 100mg, 400mg, 500mg(Bosutinib Monohydrate) |
Pfizer Korea Inc. |
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) |
Reimbursement is adequate when accepted at or below assessed value. |
|
Koselugo Caps. 10mg, 25mg(Selumetinib hydrogen sulfate) |
AstraZeneca Korea, Inc |
Neurofibromatosis type 1 with plexiform neurofibromas |
Reimbursement is adequate. |
|
Luxtuma Inj.(Voretigene Neparvovec) |
Novartis Korea Ltd |
Inherited retinal dystrophy caused by biallelic RPE65 mutations |
Reimbursement is adequate. |
|
Nucala Inj.(Mepolizumab, Recombinant DNA) |
GSK co., Ltd. |
Severe eosinophilic asthma |
Reimbursement is adequate. |
|
Fasenra Pre-filled Syringe Inj. 30mg (Benralizumab) |
AstraZeneca Korea, Inc |
Severe eosinophilic asthma |
Not reimbursed. |
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
